DK1181285T3 - 3-(Arylsulfonylamino)-tetrahydrofuran-3-carboxylsyrehydroxamider - Google Patents

3-(Arylsulfonylamino)-tetrahydrofuran-3-carboxylsyrehydroxamider

Info

Publication number
DK1181285T3
DK1181285T3 DK00922821T DK00922821T DK1181285T3 DK 1181285 T3 DK1181285 T3 DK 1181285T3 DK 00922821 T DK00922821 T DK 00922821T DK 00922821 T DK00922821 T DK 00922821T DK 1181285 T3 DK1181285 T3 DK 1181285T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
carboxylsyrehydroxamider
arylsulfonylamino
tetrahydrofuran
Prior art date
Application number
DK00922821T
Other languages
English (en)
Inventor
Lawrence Alan Pfizer In Reiter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1181285T3 publication Critical patent/DK1181285T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
DK00922821T 1999-05-28 2000-05-15 3-(Arylsulfonylamino)-tetrahydrofuran-3-carboxylsyrehydroxamider DK1181285T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13667799P 1999-05-28 1999-05-28
PCT/IB2000/000646 WO2000073294A2 (en) 1999-05-28 2000-05-15 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides

Publications (1)

Publication Number Publication Date
DK1181285T3 true DK1181285T3 (da) 2004-01-26

Family

ID=22473882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00922821T DK1181285T3 (da) 1999-05-28 2000-05-15 3-(Arylsulfonylamino)-tetrahydrofuran-3-carboxylsyrehydroxamider

Country Status (19)

Country Link
US (1) US6342521B1 (da)
EP (1) EP1181285B1 (da)
JP (1) JP3828748B2 (da)
AT (1) ATE251618T1 (da)
AU (1) AU4309800A (da)
BR (1) BR0011538A (da)
CA (1) CA2375513C (da)
DE (1) DE60005818T2 (da)
DK (1) DK1181285T3 (da)
ES (1) ES2203456T3 (da)
GT (1) GT200000084A (da)
HN (1) HN2000000052A (da)
MA (1) MA26737A1 (da)
MX (1) MXPA01012266A (da)
PE (1) PE20010204A1 (da)
PT (1) PT1181285E (da)
TN (1) TNSN00114A1 (da)
UY (1) UY26169A1 (da)
WO (1) WO2000073294A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP4343373B2 (ja) * 2000-01-14 2009-10-14 富士フイルム株式会社 写真サービスシステム及びデジタルカメラ
BR0109353A (pt) * 2000-03-21 2003-04-08 Procter & Gamble Cadeia lateral heterocìclica contendo inibidores de metaloprotease
JP2003528082A (ja) 2000-03-21 2003-09-24 ザ プロクター アンド ギャンブル カンパニー ニフッ化酪酸メタロプロテアーゼ阻害物質
SK12842002A3 (sk) 2000-03-21 2003-02-04 The Procter And Gamble Company Heterocyklický vedľajší reťazec obsahujúci N-substituované inhibítory metaloproteáz a farmaceutický prípravok s ich obsahom
US6548539B1 (en) * 2001-03-05 2003-04-15 Avalon Pharmaceuticals Agents for regulation of colon cancer gene expression
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
RS53941B1 (en) * 2009-01-12 2015-08-31 Pfizer Limited SULFONAMID DERIVATIVES
CA2804173C (en) 2010-07-09 2015-01-13 Pfizer Limited Sulfonamide nav1.7 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
CA2278694C (en) * 1997-01-23 2006-09-26 F. Hoffmann-La Roche Ag Sulfamide-metalloprotease inhibitors
DE69817801T2 (de) * 1997-02-03 2004-03-11 Pfizer Products Inc., Groton Arylsulfonylhydroxamsäurederivate
WO1999002510A1 (en) * 1997-07-10 1999-01-21 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
NZ503945A (en) * 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives

Also Published As

Publication number Publication date
PT1181285E (pt) 2004-01-30
AU4309800A (en) 2000-12-18
WO2000073294A2 (en) 2000-12-07
UY26169A1 (es) 2000-12-29
ATE251618T1 (de) 2003-10-15
PE20010204A1 (es) 2001-03-05
TNSN00114A1 (fr) 2002-05-30
WO2000073294A3 (en) 2001-03-29
BR0011538A (pt) 2002-02-26
MXPA01012266A (es) 2002-07-30
US6342521B1 (en) 2002-01-29
EP1181285A2 (en) 2002-02-27
GT200000084A (es) 2001-11-17
ES2203456T3 (es) 2004-04-16
JP2003500484A (ja) 2003-01-07
CA2375513C (en) 2006-11-28
MA26737A1 (fr) 2004-12-20
EP1181285B1 (en) 2003-10-08
DE60005818T2 (de) 2004-05-06
HN2000000052A (es) 2001-02-02
JP3828748B2 (ja) 2006-10-04
DE60005818D1 (de) 2003-11-13
CA2375513A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
GT199900132A (es) Inhibidores de tace.
AP9801174A0 (en) Cyclic sulfone derivatives.
EA199900641A1 (ru) Производные арилсульфонилгидроксамовой кислоты
BR0207378A (pt) Tratamento de câncer
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
CA2279276A1 (en) Arylsulfonylamino hydroxamic acid derivatives
NO990821L (no) Arylsulfonylamino-hydroksaminsyre-derivater
DK1181285T3 (da) 3-(Arylsulfonylamino)-tetrahydrofuran-3-carboxylsyrehydroxamider
HK1060067A1 (en) Compositions for antitumour treatment containing ecteinascidin 743
DK1181286T3 (da) 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylsyre hydroxamider
IT8323359A0 (it) Complessi platino-diamminici, procedimento per la loro preparazione, procedimento per lapreparazione di una composizione medica contenente tali complessi platino-diamminici per il trattamento del cancro, nonche'composizione cosi' realizzata.
FI1496918T3 (fi) Natriummeta-arseniitin käyttö kasvainten hoidossa
ECSP003498A (es) Hidroxiamidas de acidos 3- ( arilsulfonilamino)-tetrahidrofuran-3-carboxilicos
ECSP003494A (es) Hidroxiamidas de acidos 3- ( arilsulfonilamino)-tetrahidropiran-3-carboxilicos
IL159469A0 (en) Xenogenic oligo-or/and polyribonucleotides as agents for the treatment of malignant tumours
PT1202992E (pt) Derivados de ascididemina e suas aplicacoes terapeuticas